A substantial number of cancer cases are attributable to diabetes and high BMI. As the prevalence of these cancer risk factors increases, clinical and public health efforts should focus on identifying optimal preventive and screening measures for whole populations and individual patients (The Lancet Diabetes & Endocrinology)

Metformin prolongs the overall survival of diabetic colorectal cancer patients, but it does not affect the colorectal cancer-specific survival. Metformin may be a good choice in treating colorectal cancer patients with diabetes mellitus in clinical settings (Journal of Diabetes Research)

The use of statins offsets insulin-related cancer risks in patients with diabetes independently of sex and age. Overall, our data support the hyperglycaemia–cancer hypothesis. A reduction in endogenous or exogenous hyperinsulinaemia may be beneficial for cancer prevention. Therefore, insulin-sparing and insulin-sensitizing drugs should be the preferred treatment choices (Journal of Internal Medicine)

Metformin monotherapy may be associated with a reduction in the risk for cancer development compared with sulfonylurea monotherapy. Moreover, the use of an average defined daily dose of >0.25 of metformin when compared to lower dose will contribute to a reduction of 80% risk (Therapeutics and Clinical Risk management)

Though type 2 diabetes has been extensively studied in relation to risk of developing cancer and cancer mortality and strong claims of significance exist for most of the studied associations, only a minority of these associations have robust supporting evidence without hints of bias (BMJ)

Subscribe

Platinum Sponsors

Gold Sponsors

Silver Sponsors

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.